

About the Lighthouse Clinical Study

The purpose of the Lighthouse clinical study is to evaluate the safety and efficacy of the investigational medication, clemizole, as an additional therapy to potentially lower the number of seizures in children and adults living with Lennox-Gastaut syndrome (LGS). If someone you care about has frequent seizures from LGS, even when taking antiseizure medication(s), this clinical study may be an option.

The investigational medication, clemizole, is an oral solution that will be administered twice a day during the study. The study may last up to 3 1/2 years, including both clinic visits and phone calls.

How to Qualify

People living with LGS may be able to participate in this study if they*:

- Are at least 2 years old
- Were diagnosed with LGS
- Had onset of seizures before turning 11
- Have a lack of seizure control despite taking 1 to 4 antiseizure medications
- Have frequent seizures (an average of 4 seizures per month for the last 2 months)
- Are not enrolled in another clinical study
- * This is not a complete list of study requirements. The study doctor will review all the requirements with you and/or the potential participant.

Why Participate

- If the person living with LGS qualifies and decides to participate, they will receive:
- All study-related care and the investigational medication at no charge
- Assistance with study-related travel expenses (including food and lodging), as needed
- Close monitoring by a study doctor and study team who specialize in LGS
- The opportunity to help researchers learn more about LGS

Safety while participating in the Lighthouse clinical study is our highest priority. If any questions or concerns arise, a study team is available to help. Participation in any clinical study is always voluntary. Participants are free to leave the study at any time and for any reason. Privacy will be maintained throughout the study.



